Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib): U.S. versus global perspective on patient and disease characteristics, treatment history, and sorafenib use.
Robert C. G. Martin
Honoraria - Bayer/Onyx
Anthony B. El-Khoueiry
Consultant or Advisory Role - Bayer/Onyx
Honoraria - Bayer/Onyx
Research Funding - Bayer; Bristol-Myers Squibb
Alec Goldenberg
No relevant relationships to disclose
Alan Paul Venook
Research Funding - Bayer/Onyx
Parvez Mantry
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Research Funding - Onyx
Pierre Michel Gholam
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Research Funding - Onyx
Brendan McGuire
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Research Funding - Onyx
Arun Sanyal
Employment or Leadership Position - AASLD (U); AASLD (U)
Consultant or Advisory Role - Onyx (U); Onyx (U)
Research Funding - Bayer/Onyx; Bayer/Onyx
Jeff H. Geschwind
Consultant or Advisory Role - Bayer; Biocompatibles International; Guerbet; Nordion
Research Funding - Bayer; Biocompatibles International; CeloNova; ContextVision; Genentech; Nordion; Phillips Medical; RSNA
Jorge A. Marrero
Consultant or Advisory Role - Bayer/Onyx; Bristol-Myers Squibb
Research Funding - Bayer/Onyx; Bristol-Myers Squibb